News

STAT9h
New CBER director Vinay Prasad praises evidence, FDA reviewers in first speech to staff
WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his ...
Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation
FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and ...
The FDA names a new vaccine chief with an unsettling record, joining a controversial team
Dr. Vinay Prasad, the FDA's new vaccine chief, has been accused of spreading misinformation about Covid vaccines.
The American Journal of Managed Care15h
Biotech Stocks Slide After FDA Selects Prasad to Lead CBER
The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...
STAT22h
Women’s Health Initiative gets official word on funding
“Potential exposure to these substances is still quite small, thank goodness,” Jim Crotty, who served for over a decade in ...
Hosted on MSN21h
Sarepta price target lowered to $70 from $110 at Piper Sandler
The firm notes Tuesday has been “a doozy of a day” for Sarepta, with the announcement of Vinay Prasad as the new head of the FDA’s CBER and a miss on Q1 earnings, where Elevidys net revenue came in ...
Indian-American Vinay Prasad takes charge as US vaccine chief
Vinay Prasad, an oncologist-hematologist, has been appointed as the new director of the FDA's CBER, overseeing vaccines and ...